Literature DB >> 28960946

"Atypical" salivary gland fine needle aspiration: Risk of malignancy and interinstitutional variability.

He Wang1, Aatika Malik1, Zahra Maleki2, Esther Diana Rossi3, Bo Ping4, Ashish Chandra5, Syed Z Ali2, Guido Fadda3, Jindong Wang1, Seyedeh Elham Arab1, Huaqing Zhao1, Nirag Jhala1.   

Abstract

BACKGROUND: Fine needle aspiration (FNA) is widely used in the diagnosis of salivary gland lesions. Salivary gland FNAs are often difficult to diagnose because of morphologic heterogeneity, a small but significant number of the FNAs yield "atypical" diagnosis. However, systematic evaluation of the risk of malignancy (ROM) of the atypical diagnoses across institutions and the variability of ROM among institutions are still lacking.
METHODS: Salivary gland FNAs from five tertiary medical centers of United States, Europe and China were reviewed. Cases with "atypical" diagnosis and histological follow-up were included in this study. The diagnostic category of "atypical" was adopted from Milan System for Reporting Salivary Gland Cytopathology (MSRSGC, personal communication).
RESULTS: Among the 12,606 salivary gland FNAs, 504 (4.0%) cases were reported as "atypical", with 154 cases (30.6%) having histological follow-ups. Histological follow-ups revealed 94 malignant tumors (61.0%, 57 lymphomas, 33 carcinomas, 2 sarcomas, 1 metastatic melanoma, 1 metastatic neuroblastoma), 33 benign tumors (21.4%), and 25 benign lesions (16.2%). ROM in the subset of "atypical" cases with histological follow-up from different institutions vary from 73.08% to 0.00%, the Pearson chi2  = 24.38 and P < .001.
CONCLUSIONS: More than half of the subset of "atypical" salivary gland FNAs with histological resection turned out to be malignant tumors; another one-fourth were benign neoplasms. Further, the highly variable ROMs of the "atypical" category amongst different institutions likely reflect the variable practices at each individual institution.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  atypical; interinstitutional variability; risk of malignancy; salivary gland FNA

Mesh:

Year:  2017        PMID: 28960946     DOI: 10.1002/dc.23826

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  4 in total

1.  A Call for Universal Acceptance of the Milan System for Reporting Salivary Gland Cytopathology.

Authors:  Eric Barbarite; Sidharth V Puram; Adeeb Derakhshan; Esther D Rossi; William C Faquin; Mark A Varvares
Journal:  Laryngoscope       Date:  2019-03-08       Impact factor: 3.325

2.  Application of the Milan System for Reporting Submandibular Gland Cytopathology: An international, multi-institutional study.

Authors:  Zahra Maleki; Zubair Baloch; Ryan Lu; Khurram Shafique; Sharon J Song; Kartik Viswanathan; Rema A Rao; Holly Lefler; Aisha Fatima; Austin Wiles; Vickie Y Jo; He Wang; Guido Fadda; Celeste N Powers; Syed Z Ali; Liron Pantanowitz; Momin T Siddiqui; Ritu Nayar; Jerzy Klijanienko; Guliz A Barkan; Jeffrey F Krane; Esther D Rossi; Fabiano Callegari; Ivana Kholová; Massimo Bongiovanni; William C Faquin; Marc P Pusztaszeri
Journal:  Cancer Cytopathol       Date:  2019-05-03       Impact factor: 5.284

3.  Cytologic grading of primary malignant salivary gland tumors: A blinded review by an international panel.

Authors:  Daniel N Johnson; Mine Onenerk; Jeffrey F Krane; Esther Diana Rossi; Zubair Baloch; Güliz Barkan; Massimo Bongiovanni; Fabiano Callegari; Sule Canberk; Glen Dixon; Andrew Field; Christopher C Griffith; Nirag Jhala; Sara Jiang; Daniel Kurtycz; Lester Layfield; Oscar Lin; Zahra Maleki; Miguel Perez-Machado; Marc Pusztaszeri; Philippe Vielh; He Wang; Matthew A Zarka; William C Faquin
Journal:  Cancer Cytopathol       Date:  2020-04-08       Impact factor: 5.284

4.  The risk for malignancy using the Milan salivary gland classification categories: A 5-year retrospective review.

Authors:  Christine A Liang; Jing Liu; Jaiyeola Thomas Ogunniyi; Hui Zhu; Songlin Zhang
Journal:  Cytojournal       Date:  2019-07-25       Impact factor: 2.091

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.